prof. Vibeke Kruse
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - VIBEKE.KRUSE@UGent.be
Show
Sort by
-
- Journal Article
- A1
- open access
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial
-
- Journal Article
- A1
- open access
Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures
-
Selective oral MEK1/2 inhibitor pimasertib : a phase I trial in patients with advanced solid tumors
-
Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma : antitumor activity in a phase I, dose-escalation trial
-
Spatiotemporal evolution of radiation myositis on 18F-FDG PET/CT following hypofractionated radiotherapy of intramuscular melanoma metastases
-
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors : should we take the risk?
-
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
-
- Miscellaneous
- open access
Recommendations for skin cancer consultation and surgery during COVID‐19 pandemic
-
Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma
-
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition